Today: 22 July 2026
NIO Inc. (NYSE:NIO) rises as ES9 premium lifts June numbers
22 July 2026
1 min read

Shares in NIO Inc. (NYSE:NIO) Fall as Chip Investment Suggests Approximately $760 Million

NEW YORK, July 22, 2026, 15:08 (EDT)

NIO’s remaining interest in GeniTech is valued at around $763 million, representing 7.8% of NIO’s market capitalisation of $9.75 billion. The figure is based on publicly disclosed financing details and the most recent share count.

This is significant as GeniTech represented a major research segment for NIO. External investment now attaches a transparent value to some of those expenditures.

NIO shares declined by 2.5% to $4.67 in late trading on Wednesday. The latest quote was recorded while the U.S. market was still open at 15:08 EDT.

Tim Hsiao and his team at Morgan Stanley pointed to the change on Tuesday, noting that GeniTech brings NIO “one step away from a cash-burnt EV maker.” CnEVPost

The bank reported that shipments of the NX9031 family topped 300,000 units. The main processor is currently used in both NIO and Onvo vehicles. Morgan Stanley said expanding into licensing and robotics may broaden revenue streams.

NIO announced in February that investors agreed to purchase a 27.3% stake for 2.257 billion yuan. The company will keep 62.7% ownership and will maintain GeniTech’s consolidation.

The terms indicate an equity valuation of 8.27 billion yuan. NIO’s stake amounts to 5.18 billion yuan, equivalent to roughly $763 million. The calculation is based on a rate of 6.7933 yuan to the dollar.

The financing details and first-quarter numbers allow for this comparison. The dollar figure represents an inferred estimate rather than an actual trading price.

MeasureAmountRelative scale
External funding in GeniTechRMB 2.257 billion1.20 times NIO’s Q1 R&D
GeniTech estimated full equity valueRMB 8.27 billionEntire chip business
NIO’s remaining 62.7% ownershipRMB 5.18 billion / $763 million7.8% of NIO’s market capitalization
NIO Q1 research and development spendingRMB 1.885 billionStated quarterly benchmark

The outside cash amounts to 1.2 times NIO’s research budget for the first quarter. NIO reported a 40.7% decline in R&D expenditure compared to a year ago.

Investor focus on the chip asset is driven by vehicle margins. Vehicle margin for the first quarter was 18.8%. Adjusted operating profit stood at 66.8 million yuan, reflecting continued thin profitability.

Reduced chip expenses or prospective royalty earnings may increase those numbers. Upcoming disclosures will need to demonstrate the impact.

Car sales remain central to the equity story. NIO handed over 107,658 vehicles in the second quarter, marking an increase of 49.4%. Deliveries in June totaled 40,597.

Shares of other Chinese electric vehicle companies listed in the U.S. lost ground as well. XPeng Inc. fell 3.0%, while Li Auto Inc. edged down 0.5%.

Risks are still significant. The valuation is based on a February private funding round, rather than a public market price. The Morgan Stanley note did not disclose licensing quantities or individual chip sales.

Investors can now quantify the chip stake. The bigger challenge is determining if it boosts margins or cash flow.

Marcin Frąckiewicz is the founder and CEO of TS2 Space, a satellite communications company serving customers around the world. A graduate of the Warsaw School of Economics (SGH), he has more than two decades of experience in telecommunications, satellite services and technology ventures. He writes about satellite communications, space technology, artificial intelligence and the stock market, with a particular focus on technology companies, semiconductors, emerging industries and the trends shaping global innovation. Follow Marcin Frąckiewicz on Google News, Facebook. or Linkedin.

Stock Market Today

  • City Holding (NASDAQ:CHCO) Tops Q2 CY2026 Revenue, EPS Forecasts
    July 22, 2026, 4:29 PM EDT. City Holding (NASDAQ:CHCO) posted Q2 CY2026 revenue of $81.74 million, up 4.1% year-on-year and surpassing expectations by 1.3%. Adjusted EPS reached $2.35, coming in 5.6% higher than analysts' consensus. Net Interest Income totaled $60.76 million, an increase of 2.8% and matching projections. The efficiency ratio improved to 48.1%, beating forecasts. Market capitalization is at $1.9 billion, with tangible book value per share rising to $46.40.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares rise 23% after Plozasiran Phase 3 data released
Previous Story

Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares rise 23% after Plozasiran Phase 3 data released

Bank of America Corporation (NYSE:BAC) approaches 52-week peak, diminishing buyback impact as shares climb
Next Story

Bank of America Corporation (NYSE:BAC) approaches 52-week peak, diminishing buyback impact as shares climb

Go toTop